Her-2 negative
Showing 1 - 25 of >10,000
HER2-low in Metastatic Breast Cancer Patients
Not yet recruiting
- HER2-negative
- (no location specified)
Nov 9, 2023
Breast Cancer Trial in Beijing (Mitoxantrone HCl liposome, Capecitabine)
Not yet recruiting
- Breast Cancer
- Mitoxantrone hydrochloride liposome
- Capecitabine
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Dec 1, 2023
HER2-low in Unresectable and/or Metastatic Breast Cancer
Not yet recruiting
- Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
- (no location specified)
Nov 6, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
Breast Cancer Trial in Xi'an (metronomic oral vinorelbine plus anlotinib)
Recruiting
- Breast Cancer
- metronomic oral vinorelbine plus anlotinib
-
Xi'an, Shaanxi, ChinaXi'an International Medical Center Hospital
Aug 27, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)
Recruiting
- Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
-
Guangzhou, Guangdong, ChinaSun-yat sen university cancer center
Jan 27, 2023
Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for
Recruiting
- Breast Cancer
- Dalcelli、Exemestane、Gosserine
- Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
-
Tianjin, Tianjin, ChinaJie Ge
Aug 20, 2023
Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer
Active, not recruiting
- Hormone-receptor-positive Breast Cancer
- +2 more
- No drug
-
Cambridge, MassachusettsConcertAI database
Sep 8, 2023
Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- toripalimab FOLFOX
- (no location specified)
Aug 3, 2023
Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)
Recruiting
- Her-2 Negative Breast Cancer
- HRR Gene Mutation
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023
Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer Trial in New Haven (Dapagliflozin 10mg)
Not yet recruiting
- Breast Cancer
- +2 more
- Dapagliflozin 10mg
-
New Haven, ConnecticutYale Cancer Center Smilow Cancer Hospital
Aug 3, 2023
Breast Tumors Trial in Guangzhou (procedure, drug, biological)
Recruiting
- Breast Neoplasms
- Sentinel Lymph Node Biopsy (SLNB)
- +7 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023
Integrating Person-based Care in Treatment of Advanced
Recruiting
- Advanced Breast Cancer
- Sharing all key aspects associated with the quality of life in a single digital environment
-
Rome, ItalyFondazione Policlinico A. Gemelli - IRCCS
May 29, 2023
Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)
Enrolling by invitation
- Germline BRCA-mutated HER2-negative Breast Cancer
-
Beijing, Beijing, ChinaBreast Cancer, Peking University People's Hospital
Nov 14, 2022
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal
Active, not recruiting
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
- +2 more
-
Ulm, Baden-Württemberg, GermanyUniversity Hospital Ulm -Department of Gynecology
Jul 27, 2022
Breast Tumors Trial in Guangzhou (procedure, drug, biological)
Recruiting
- Breast Neoplasms
- Surgery for harvesting tumor-draining lymph nodes
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023
Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)
Not yet recruiting
- Breast Cancer
- Dalpiciclib combined with Letrozole
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 3, 2023
HER2-negative Breast Cancer, Advanced Breast Cancer Trial in Guangzhou (Organoid-guided treatment, Taxane, Capecitabine)
Not yet recruiting
- HER2-negative Breast Cancer
- Advanced Breast Cancer
- Organoid-guided treatment
- +5 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Oct 22, 2023
Luminal B/HER2-negative Breast Cancer Trial in Hangzhou (Dalpiciclib combined with aromatase inhibitors,
Recruiting
- Luminal B/HER2-negative Breast Cancer
- Dalpiciclib combined with aromatase inhibitors
- anthracycline-cyclophosphamide followed by taxane
-
Hangzhou, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 30, 2022
Breast Tumors Trial in Guangzhou (procedure, drug, biological)
Recruiting
- Breast Neoplasms
- Surgery for harvesting tumor-draining lymph nodes
- +8 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2023